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Preliminary results for the 2014/15 season indicate low 
to null effect of vaccination against influenza A(H3N2)-
related disease. As of week 5 2015, there have been 
1,136 hospital admissions, 210 were due to influenza 
and 98% of subtype A strains were H3. Adjusted influ-
enza vaccine effectiveness was 33% (range: 6–53%) 
overall and 40% (range: 13% to 59%) in those 65 years 
and older. Vaccination reduced by 44% (28–68%) the 
probability of admission with influenza.
Introduction
The 2014/15 influenza season in the northern hemi-
sphere is characterised by the circulation of A(H3N2) 
viruses belonging to clade 3C.2a and 3C.3a, distinct 
from the A/Texas/50/2012(H3N2)-like (clade 3C.1) ref-
erence strain used in the 2014/15 northern hemisphere 
vaccine [1]. Preliminary influenza vaccine effectiveness 
(IVE) estimates from Canada [2,3] and Europe [4], report 
a null effect of the current vaccine in preventing labo-
ratory-confirmed influenza A(H3N2) with 3.4% (95% 
confidence interval: (−44.8 to 35.5) against medically 
attended acute respiratory infection (ARI) and −16.8% 
(−48.9 to 8.3) against hospital admissions. Early esti-
mates from the United States (US) [5], reported a low 
effect of 23% (8–36%) against medically attended ARI 
associated with laboratory-confirmed influenza.
An active annual surveillance scheme in the Valencia 
Region in Spain monitors IVE in preventing laboratory-
confirmed influenza requiring hospitalisation [6]. In 
the current season, a split trivalent vaccine (Vaxigrip; 
SANOFI PASTEUR MSD, S.A. Madrid, Spain) was 
acquired by public tender and offered free of charge to 
non-institutionalised people targeted for influenza vac-
cination because of age or the presence of comorbidity 
[7].
We report 2014/15 influenza IVE in preventing lab-
oratory-confirmed influenza admissions in patients 
admitted during the first eight weeks of the 2014/15 
influenza season, from 7 December 2014 to 25 January 
2015.
Methods
We performed a test-negative study in 10 hospitals 
that provide healthcare to 48% of the 4,937,044 inhab-
itants of Valencia. The influenza season began in week 
50 2014 (Figure 1), as defined by two or more positive 
2 www.eurosurveillance.org
influenza hospitalisations identified in two consecu-
tive weeks.
Study procedures have been published [6]. Study staff 
screened emergency admissions for eligible subjects. 
Patients were included after written consent if they 
reported symptoms of influenza-like illness (ILI) [8] 
within seven days of admission. We collected a com-
bined nasopharyngeal and pharyngeal flocked swab 
and sociodemographic and clinical information. A 
patient was considered immunised if they had received 
influenza vaccine more than 14 days before the onset 
of ILI (as recorded by the Vaccine Information System 
or by recall).
Laboratory confirmation was by semiquantitative 
reverse-transcription polymerase chain reaction. The 
specimens were tested in a centralised virology labo-
ratory at Fundación para el Fomento de la Investigación 
Sanitaria y Biomédica (the Foundation for the Promotion 
of Health and Biomedical Research; FISABIO) following 
the World Health Organization (WHO) protocol [9].
Influenza-positive admissions were compared (vac-
cination odds ratio (OR)) with influenza-negative 
admissions [10,11]. Adjusted IVE was defined as 100 x 
(1 - adjusted OR). We defined two groups for IVE esti-
mation: (i) all subjects 18 years and older targeted for 
vaccination, and (ii) subjects aged 65 and older. Other 
subgroups were not considered to avoid a sparse-num-
bers bias [2,12]. The sample size sufficient to provide 
80% statistical power to detect an IVE of at least 50%, 
for a vaccine coverage of 50 to 60%, with a delta of 
10%, was 130 to 150 influenza cases.
The adjusted OR were obtained by logistic regression. 
Previous knowledge and directed acyclic graphs (DAG) 
[13,14] were used to define the variables finally used 
to improve comparability and exchangeability between 
vaccinated and non-vaccinated subjects and to clarify 
the minimum set of variables to be included in the 
regression logistics models and in the inverse prob-
ability-weighted regression adjustment models. The 
roles of ‘previous vaccination’ as an instrumental varia-
ble highly correlated with current vaccination and ‘time 
to swab’, which cannot be considered a confounder but 
is clearly related to outcome, were made explicit with 
the use of DAG. We assessed departure from linearity 
in categorical ordered variables, interaction between 
potential confounders and vaccination, and clustering 
by enrolment site or epidemiological week.
Figure 1
Hospital admissions with laboratory-confirmed influenza 
per week, Valencia, 7 December 2014–28 January 2015 
(n = 210) 
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Numbers on top of bars: percentage of samples positive for 
influenza.
Source: Valencia Hospital Network for the Study of Influenza and 
Other Respiratory Viruses (VAHNSI).
Figure 2
Flowchart showing exclusion criteria, study of mid-season 
influenza vaccine effectiveness in preventing hospital 
admissions related to influenza, Valencia, 7 December 
2014–28 January 2015 (n = 3,988 )
Elegible
(n=3,988)
  No consent (n=542)
  
  Excluded:
  No ILI symptoms (n=1,363)
  Onset >7 days before admission (n=320)
  Not targeted for influenza vaccination (n=79)
  Samples not yet processed (n=337)
  Sample inadequate (n=1)
Admissions included in the analysis
 (n=1,346)
 Influenza-positive
 (n=210)
Influenza-negative 
(n=1,136)
ILI: influenza-like illness.
Source: Valencia Hospital Network for the Study of Influenza.
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Table 1
Characteristics of included hospital admissions, Valencia, 7 December 2014–28 January 2015 (n = 1,346)
Test result status Vaccination status
Influenza-positive Influenza-negative
p value
Vaccinated
p value
n % n % n Total %
Overall 210 100 1,136 100 832 1,346 61.8
Sex 0.275 0.002
Male 112 53.3 652 57.4 499 764 65.3
Female 98 46.7 484 42.6 333 582 57.2
Age group (years) 0.824 0
18–64 36 17.1 202 17.8 85 238 35.7
≥ 65 174 82.9 934 82.2 747 1,108 67.4
Risk factors (number) 0.034 0.001
0 28 13.3 99 8.7 63 127 49.6
1 77 36.7 376 33.1 269 453 59.4
≥ 2 105 50.0 661 58.2 500 766 65.3
Admission in the past 12 months 0.029 0.015
No 142 67.6 677 59.6 485 819 59.2
Yes 68 32.4 459 40.4 347 527 65.8
Outpatient contacts 0.742 0
0 39 18.6 227 20 132 266 49.6
1 37 17.6 216 19 148 253 58.5
2 54 25.7 254 22.4 198 308 64.3
≥ 3 80 38.1 439 38.6 354 519 68.2
Smoking habits 0.106 0
Never 109 51.9 501 44.1 379 610 62.1
Ex-smoker 71 33.8 458 40.3 360 529 68.1
Current 30 14.3 177 15.6 93 207 44.9
Days from onset to swab 0.805 0.632
≤ 2 53 25.2 275 24.2 203 328 61.9
3–4 86 41.0 493 43.4 367 579 63.4
5–7 65 31.0 326 28.7 235 391 60.1
> 7 6 2.9 42 3.7 27 48 56.3
Influenza test result  0.552
Negative 1,136 100.0 722 1,136 63.6
A(H1N1)pdm09 2 1.0 1 2 50.0
A(H3N2) 99 47.1 47 99 47.5
A subtype pending 97 46.2 56 97 57.7
B 12 5.7 6 12 50
Vaccinated 2013/14 0.15 0
No 93 44.3 443 39 98 536 18.3
Yes 117 55.7 693 61 734 810 90.6
Vaccinated 2012/13 0.369 0
No 95 45.2 476 41.9 148 571 25.9
Yes 115 54.8 660 58.1 684 775 88.3
Source: Valencia Hospital Network for the Study of Influenza.
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We used inverse probability-weighted regression 
adjustment to estimate the vaccination average effect 
from observed data [15,16] after conditioning influenza 
admissions on indicator variables: age in deciles, epi-
demiological week, number of comorbidities, smok-
ing habits, hospital admission in the last 12 months, 
number of outpatient contacts in the last three months, 
time to swab, and recruitment hospital. We conditioned 
vaccination on the same covariates, excluding time to 
swab and adding influenza vaccination in the past two 
seasons.
Sensitivity analyses were performed according to time 
to swab and vaccination ascertainment in the vaccine 
information system. All probabilities were two-tailed; 
p < 0.05 was considered significant. Analyses were per-
formed with Stata 13.1 (StataCorp, College Station, TX).
The Ethics Research Committee of the Dirección General 
de Salud Pública-Centro Superior de Investigación en 
Salud Pública (DGSP-CSISP) approved the protocol of 
the study.
Results
We enrolled 1,136 hospital admissions, 210 with influ-
enza (Figure 2), 196 of them influenza A.  Of the 101 
influenza  A subtyped strains, 99 (98%) were H3. Of 
all admissions, 1,108 (82%) were patients older than 65 
years (Table 1). Of the 210 influenza-positive patients, 
110 (52%) were vaccinated compared with 722 (64%) of 
1,136 influenza-negative patients (Table 2).
Adjusted IVE was 33% (6–53%) overall and 40% (13– 
59%) in those 65 years and older (Table 2). The prob-
ability of influenza-related admission in vaccinated 
individuals was 13% (10–15%) compared with 22% 
(18–27%) in those unvaccinated (data not shown). 
Vaccination reduced by 44% (28–68%) the overall 
probability of hospital admission with influenza (Table 
2). These results were not altered in the sensitivity 
analysis (Table 2).
Discussion
Our estimate suggests that the 2014/15 influenza vac-
cine was moderately effective in preventing hospital 
admissions related to influenza in a season in which 
Table 2
Influenza vaccine effectiveness, preliminary results, Valencia, 7 December 2014–28 January 2015 (n = 1,346)
Influenza-positive Influenza-negative
OR (95% CI) Adjusted
a 
OR (95% CI)
AVEb (95% 
CI)Vaccinated Total sample Vaccinated Vaccinated Total sample Vaccinated
n n % n n %
Overall 110 210 52.4 722 1,136 63.6 0.63(0.47–0.85)
0.67
(0.47–0.94)
44
(28–60)
≥ 65 96 174 55.2 651 934 69.7 0.53(0.38–0.74)
0.60
(0.41–0.87)
48
(32–64) 
Swab (≤ 4 days)
Overall 78 139 56.1 492 768 64.1 0.72(0.50–1.04)
0.79
(0.51–1.21)
32
(11–53)
≥ 65 68 115 59.1 448 642 69.8 0.62(0.41–0.94)
0.73
(0.46–1.18)
32
(9–55)
VIS
Overall 108 185 58.4 720 987 73.0 0.52(0.38–0.72)
0.54
(0.37–0.78)
49
(34–63)
≥ 65 95 157 60.5 649 838 77.5 0.44(0.31–0.64)
0.49
(0.33–0.74)
50
(35–66)
VIS and Swabc
Overall 76 120 63.3 490 677 72.4 0.66(0.44–0.99)
0.67
(0.41–1.09)
37
(17–57)
≥ 65 67 103 65.1 446 581 76.8 0.56(0.36–0.88)
0.62
(0.36–1.05)
37
(15–59)
AVE: average vaccination effect; CI: confidence interval; OR: odds ratio; VIS: vaccine Information system.
a Adjusted by indicator variables: sex, age in deciles, smoking (never, ex-smoker, current smoker), number of outpatient contacts in the past 
three months (0, 1, 2, > 2), number of comorbidities (0, 1, 2, ≥ 2), hospital admissions in the past 12 months (yes, no), recruitment hospital, 
epidemiological week of admission, days from onset of symptoms to swab (≤ 2, 3–4, 5–7, > 7).
b Average vaccination effect (percentage of reduction) on the probability of admission with confirmed influenza. Admission with influenza 
was conditioned on age in deciles, smoking (never, ex-smoker, current smoker), number of outpatient contacts in the past three months (0, 
1, 2, > 2), number of comorbidities (0, 1, 2, ≥ 2), hospital admissions in the past 12 months (yes, no), recruitment hospital, epidemiological 
week of admission, days from onset of symptoms to swab (≤ 2, 3–4, 5–7, > 7).  Vaccination was conditioned on the same indicator variables, 
but days to swab was omitted and record of influenza vaccination in 2012 and 2013 were added to the model.
c Patients included are those with records of any vaccination in the VIS and swabbed ≤ 4 days after symptoms onset.
Source: Valencia Hospital Network for the Study of Influenza.
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most influenza A(H3N2) viruses were different from 
the component in the 2014/15 influenza vaccine [17]. 
We can only provide information regarding the genetic 
characteristics of strains analysed at the Centro 
Nacional de Microbiología, Instituto de Salud Carlos III 
in Madrid [17]. According to their data, 67% of A(H3N2) 
clades could be considered antigenically and geneti-
cally different from the vaccine strain. We cannot make 
inferences regarding the impact on IVE of the type of 
vaccine used in Valencia as only one brand of vaccine 
was used throughout the region (99% of doses accord-
ing to the vaccination registry).
Previous reviews and reports have shown that the 
trivalent inactivated vaccine can confer substantial 
protection against mismatched influenza A [18-20]. 
Unfortunately, data from mismatched seasons on IVE 
in people 65 years and older are scarce [21].
There can be considerable variation in reported IVE 
estimates due to differences in strain circulation 
among countries, strain proportion within one region, 
the vaccines used, age-specific vaccine coverage, the 
population studied, season definition, case definition, 
ascertainment of vaccination status, differences in the 
period of surveillance, the variables included or omit-
ted in the statistical model, how they are modelled, 
and measured outcome (admission, outpatient con-
tact or infection) [11]. A major caveat are sparse num-
bers. The absence of statistical significance should be 
expected in studies with low vaccine coverage, IVE or a 
limited sample size [2,12], as reflected in our sensitiv-
ity analysis (Table 2).
Influenza VE estimates generated from surveillance 
data using the test-negative design have already been 
presented at the WHO’s annual strain selection meet-
ing [11] as a way to improve the vaccine composition. 
However, variation in the estimates may undermine 
their credibility and usefulness, particularly early in 
the season. It is important to focus on sufficient sam-
ple size, robustness of the design, representativeness 
of the population, and validity of adjustment to inform 
vaccine reformulation and vaccination policies based 
on epidemiological data.
Our results support the substantial benefit of vaccina-
tion in preventing hospital admissions with laboratory-
confirmed influenza in the first weeks of the 2014/15 
season in Valencia.
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